LOGIN  |  REGISTER
Assertio

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 489.10
3.21 0.66
1.15M
257.53M
US$ 125.960B
US$ 563.16
13.88 2.53
808,689
108.07M
US$ 60.860B
US$ 596.20
8.61 1.47
301,350
59.80M
US$ 35.650B
US$ 234.56
4.06 1.76
572,930
128.98M
US$ 30.250B
US$ 98.76
0.51 0.52
681,407
239.74M
US$ 23.680B
US$ 24.61
1.56 6.77
3.40M
737.45M
US$ 18.150B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 32.60
0.41 1.27
2.51M
444.30M
US$ 14.480B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 72.65
2.45 3.49
1.47M
178.90M
US$ 13.000B
US$ 20.04
0.49 2.51
1.13M
635.24M
US$ 12.730B
US$ 284.73
-0.46 -0.16
298,267
44.64M
US$ 12.710B
US$ 59.17
0.35 0.60
1.14M
190.58M
US$ 11.280B
US$ 58.21
0.48 0.83
1.15M
192.65M
US$ 11.210B
US$ 36.19
0.04 0.11
2.21M
285.58M
US$ 10.340B
US$ 101.38
1.28 1.28
1.90M
101.25M
US$ 10.260B
US$ 165.05
6.90 4.36
626,445
59.81M
US$ 9.870B
US$ 24.72
-0.48 -1.91
6.53M
384.82M
US$ 9.510B
US$ 48.10
-1.88 -3.76
2.69M
158.89M
US$ 7.640B
US$ 58.79
-0.03 -0.05
1.49M
127.23M
US$ 7.480B
US$ 10.15
0.13 1.30
2.54M
727.95M
US$ 7.390B
US$ 36.76
0.56 1.55
1.24M
184.80M
US$ 6.790B
US$ 301.66
-6.12 -1.99
237,403
21.81M
US$ 6.580B
US$ 62.24
-2.36 -3.65
1.54M
104.78M
US$ 6.520B
US$ 33.87
0.02 0.06
1.36M
188.99M
US$ 6.400B
US$ 102.78
1.23 1.21
998,778
60.45M
US$ 6.210B
US$ 32.80
-0.66 -1.97
1.79M
183.45M
US$ 6.020B
US$ 38.32
0.11 0.29
1.04M
155.66M
US$ 5.960B
US$ 84.69
2.58 3.14
620,678
63.53M
US$ 5.380B
US$ 53.79
-0.15 -0.28
1.89M
95.52M
US$ 5.140B
US$ 104.46
-0.01 -0.01
327,539
48.46M
US$ 5.060B
US$ 21.31
0.08 0.38
2.56M
236.39M
US$ 5.040B
US$ 168.57
3.87 2.35
291,168
28.76M
US$ 4.850B
US$ 58.92
0.62 1.06
728,635
81.83M
US$ 4.820B
US$ 71.64
1.67 2.39
683,041
65.62M
US$ 4.700B
US$ 39.48
0.33 0.84
1.05M
118.01M
US$ 4.660B
US$ 28.40
0.05 0.18
828,011
157.90M
US$ 4.480B
US$ 27.00
-0.20 -0.74
1.66M
161.80M
US$ 4.370B
US$ 30.65
1.53 5.25
1.70M
124.64M
US$ 3.820B
US$ 61.74
0.40 0.65
430,113
61.46M
US$ 3.790B
US$ 9.11
-0.25 -2.67
116,597
411.34M
US$ 3.750B
US$ 62.02
-7.31 -10.54
357,355
54.07M
US$ 3.350B
US$ 35.69
0.71 2.03
674,214
92.34M
US$ 3.300B
US$ 37.77
-0.01 -0.03
1.03M
85.35M
US$ 3.220B
US$ 26.66
0.90 3.49
1.51M
119.31M
US$ 3.180B
US$ 28.84
-0.10 -0.35
758,311
108.94M
US$ 3.140B
US$ 69.98
0.05 0.07
1.20M
43.12M
US$ 3.020B
US$ 43.06
1.15 2.74
317,118
68.46M
US$ 2.950B
US$ 15.71
-0.15 -0.95
308,574
186.89M
US$ 2.940B
US$ 19.47
0.30 1.56
1.53M
149.57M
US$ 2.910B
US$ 30.75
0.99 3.33
914,881
93.62M
US$ 2.880B
US$ 30.42
0.84 2.84
574,570
92.74M
US$ 2.820B
US$ 37.92
0.18 0.48
1.41M
74.39M
US$ 2.820B
US$ 46.28
0.48 1.05
489,085
59.60M
US$ 2.760B
US$ 22.52
0.33 1.49
692,885
119.27M
US$ 2.690B
US$ 35.11
1.33 3.94
813,554
76.24M
US$ 2.680B
US$ 37.63
0.19 0.51
501,508
69.80M
US$ 2.630B
US$ 15.15
0.31 2.09
999,017
169.28M
US$ 2.560B
US$ 8.29
-0.03 -0.36
28,259
301.94M
US$ 2.500B
US$ 14.73
-2.84 -16.16
1.19M
166.39M
US$ 2.450B
US$ 38.33
1.36 3.68
253,654
63.06M
US$ 2.420B
US$ 31.14
-0.39 -1.24
677,939
77.50M
US$ 2.410B
US$ 18.20
0.04 0.22
2.03M
124.39M
US$ 2.260B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 20.37
1.69 9.05
2.07M
101.12M
US$ 2.060B
US$ 6.83
0.13 1.94
3.04M
298.81M
US$ 2.040B
US$ 41.23
0.41 1.00
316,215
49.36M
US$ 2.040B
US$ 104.97
0.35 0.33
103,874
18.90M
US$ 1.980B
US$ 39.10
0.35 0.90
415,166
48.00M
US$ 1.880B
US$ 49.25
-0.14 -0.28
355,115
38.23M
US$ 1.880B
US$ 12.74
0.19 1.51
944,764
143.92M
US$ 1.830B
US$ 2.47
-0.01 -0.40
4.62M
730.16M
US$ 1.800B
US$ 16.34
0.31 1.93
264,792
107.05M
US$ 1.750B
US$ 56.43
-0.85 -1.48
20,006
30.88M
US$ 1.740B
US$ 29.69
1.00 3.49
354,225
58.63M
US$ 1.740B
US$ 25.97
0.95 3.80
453,066
64.77M
US$ 1.680B
US$ 24.69
0.18 0.73
245,598
65.90M
US$ 1.630B
US$ 12.30
0.46 3.89
784,362
131.84M
US$ 1.620B
US$ 28.46
0.52 1.86
439,805
57.03M
US$ 1.620B
US$ 27.66
0.52 1.92
575,061
57.03M
US$ 1.580B
US$ 20.64
0.42 2.08
1.06M
76.13M
US$ 1.570B
US$ 7.40
0.18 2.49
3.30M
207.13M
US$ 1.530B
US$ 13.01
0.05 0.39
1.56M
117.04M
US$ 1.520B
US$ 17.08
0.90 5.56
1.63M
86.43M
US$ 1.480B
US$ 33.11
1.07 3.34
342,434
43.42M
US$ 1.440B
US$ 28.41
0.54 1.94
186,539
50.03M
US$ 1.420B
US$ 17.00
0.38 2.29
1.10M
82.81M
US$ 1.410B
US$ 14.51
-0.37 -2.49
1.55M
97.19M
US$ 1.410B
US$ 11.24
-0.11 -0.97
2.37M
124.43M
US$ 1.400B
US$ 10.31
-0.34 -3.19
2.85M
131.46M
US$ 1.360B
US$ 21.29
0.05 0.24
641,771
63.32M
US$ 1.350B
US$ 14.92
0.35 2.40
1.09M
87.03M
US$ 1.300B
US$ 13.45
0.42 3.22
980,999
94.69M
US$ 1.270B
US$ 14.44
0.19 1.33
1.18M
88.07M
US$ 1.270B
US$ 4.54
0.01 0.22
1.39M
275.78M
US$ 1.250B
US$ 21.76
3.23 17.43
5.80M
57.26M
US$ 1.250B
US$ 42.17
1.16 2.83
336,201
29.76M
US$ 1.250B
US$ 10.72
0.41 3.98
155,699
115.65M
US$ 1.240B
US$ 18.30
0.50 2.81
444,996
66.34M
US$ 1.210B
US$ 13.72
0.04 0.29
595,890
84.64M
US$ 1.160B
US$ 7.31
0.14 1.95
1.64M
157.22M
US$ 1.150B
US$ 4.82
0.22 4.78
5.04M
236.85M
US$ 1.140B
US$ 18.27
0.18 1.00
723,954
62.60M
US$ 1.140B
US$ 7.75
0.08 1.04
900,348
143.18M
US$ 1.110B
US$ 7.33
-0.16 -2.14
1.24M
147.58M
US$ 1.080B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 13.13
0.48 3.79
790,842
79.21M
US$ 1.040B
US$ 11.54
0.49 4.43
1.81M
85.36M
US$ 985.050M
US$ 6.00
-0.20 -3.23
4.28M
160.18M
US$ 961.080M
US$ 3.06
-0.01 -0.33
9.60M
304.78M
US$ 932.630M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 5.92
0.08 1.37
927,060
152.52M
US$ 902.920M
US$ 16.53
0.46 2.86
168,297
48.86M
US$ 807.660M
US$ 7.91
0.08 1.02
1.27M
101.77M
US$ 805.000M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 11.53
0.28 2.49
369,297
68.88M
US$ 794.190M
US$ 1.27
0.03 2.42
8.12M
604.50M
US$ 767.720M
US$ 18.27
0.25 1.39
23,397
41.94M
US$ 766.240M
US$ 8.88
0.94 11.84
103,648
85.82M
US$ 762.080M
US$ 14.00
0.28 2.04
10,062
54.23M
US$ 759.220M
US$ 8.95
0.11 1.24
349,744
84.82M
US$ 759.140M
US$ 12.67
0.25 2.01
704,283
59.80M
US$ 757.670M
US$ 5.50
0.06 1.10
689,000
137.72M
US$ 757.460M
US$ 7.23
0.37 5.39
2.82M
101.85M
US$ 736.380M
US$ 10.24
0.44 4.49
1.32M
70.84M
US$ 725.400M
US$ 7.88
0.03 0.38
771,244
91.51M
US$ 721.100M
US$ 2.42
-0.61 -20.13
2.98M
295.37M
US$ 714.800M
US$ 6.06
0.17 2.89
993,914
117.58M
US$ 712.530M
US$ 3.12
-0.08 -2.50
281,471
224.34M
US$ 699.940M
US$ 13.00
3.61 38.45
14.40M
53.44M
US$ 694.720M
US$ 6.84
0.08 1.18
1.18M
100.85M
US$ 689.810M
US$ 9.70
0.18 1.89
606,812
69.98M
US$ 678.810M
US$ 6.33
0.18 2.93
2.17M
106.34M
US$ 673.130M
US$ 13.35
-0.15 -1.11
379,482
49.77M
US$ 664.430M
US$ 12.16
0.40 3.40
521,734
54.42M
US$ 661.750M
US$ 1.97
0.09 4.79
2.95M
335.57M
US$ 661.070M
US$ 23.82
0.76 3.30
217,868
27.50M
US$ 655.050M
US$ 33.79
3.97 13.31
450,179
18.64M
US$ 629.850M
US$ 20.55
1.49 7.82
594,495
30.43M
US$ 625.340M
US$ 4.95
0.53 11.99
78,749
126.19M
US$ 624.640M
US$ 8.00
0.37 4.85
638,043
76.96M
US$ 615.300M
US$ 4.11
0.03 0.74
1.89M
149.08M
US$ 612.720M
US$ 18.14
0.24 1.34
167,638
33.70M
US$ 611.320M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 3.15
-0.06 -1.87
736,222
189.49M
US$ 596.890M
US$ 12.00
0.26 2.21
488,022
49.42M
US$ 593.040M
US$ 8.60
0.95 12.42
3.17M
68.71M
US$ 590.910M
US$ 19.50
0.52 2.74
172,115
29.60M
US$ 577.200M
US$ 14.07
0.54 3.99
1.33M
40.51M
US$ 569.980M
US$ 6.83
0.27 4.04
12,413
81.20M
US$ 554.600M
US$ 8.09
0.00 0.00
0
67.84M
US$ 548.830M
US$ 6.07
-0.03 -0.49
681,580
89.37M
US$ 542.480M
US$ 3.41
0.00 0.00
0
153.89M
US$ 524.760M
US$ 4.26
0.15 3.65
204,935
121.55M
US$ 517.800M
US$ 3.01
0.08 2.73
459,994
171.62M
US$ 516.580M
US$ 11.25
1.61 16.70
1.48M
45.47M
US$ 511.540M
US$ 9.20
-0.06 -0.65
328,534
53.81M
US$ 495.050M
US$ 7.91
0.74 10.32
1.45M
62.42M
US$ 493.740M
US$ 4.37
0.10 2.34
1.13M
110.46M
US$ 482.710M
US$ 5.29
0.27 5.38
2.14M
89.70M
US$ 474.510M
US$ 9.10
0.40 4.60
192,073
52.03M
US$ 473.470M
US$ 8.78
0.36 4.28
315,433
53.60M
US$ 470.610M
US$ 0.36
0.11 41.83
6.25M
1.32B
US$ 469.920M
US$ 7.67
0.15 1.99
2.02M
60.68M
US$ 465.420M
US$ 7.89
0.28 3.68
686,249
58.23M
US$ 459.430M
US$ 5.90
0.15 2.61
939,210
77.76M
US$ 458.780M
US$ 7.43
0.06 0.81
602,969
61.17M
US$ 454.490M
US$ 8.92
0.31 3.60
225,834
50.60M
US$ 451.350M
US$ 2.69
0.08 3.07
1.58M
167.38M
US$ 450.250M
US$ 2.06
0.16 8.42
4.53M
218.18M
US$ 449.450M
US$ 5.99
-0.19 -3.07
575,137
71.40M
US$ 427.690M
US$ 8.62
0.02 0.23
159,175
49.17M
US$ 423.850M
US$ 5.77
0.31 5.68
1.15M
73.33M
US$ 423.110M
US$ 5.41
0.09 1.69
407,985
78.15M
US$ 422.790M
US$ 16.01
1.49 10.26
343,006
25.64M
US$ 410.500M
US$ 9.67
-0.72 -6.93
732,867
42.20M
US$ 408.070M
US$ 7.69
0.13 1.72
419,627
52.97M
US$ 407.340M
US$ 1.39
0.02 1.46
1.05M
292.87M
US$ 407.090M
US$ 6.40
0.24 3.90
127,008
63.35M
US$ 405.440M
US$ 16.74
-0.01 -0.06
1,300
23.94M
US$ 400.830M
US$ 6.78
0.02 0.30
416,954
57.95M
US$ 392.900M
US$ 4.59
0.08 1.77
2.59M
84.66M
US$ 388.590M
US$ 5.68
0.12 2.16
537,335
68.25M
US$ 387.320M
US$ 2.88
0.13 4.88
8,754
133.17M
US$ 383.530M
US$ 7.15
0.10 1.42
400,315
53.38M
US$ 381.670M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 10.24
0.25 2.50
166,951
37.13M
US$ 380.210M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 14.34
0.26 1.85
256,794
26.05M
US$ 373.560M
US$ 1.67
0.09 5.70
1.36M
223.27M
US$ 372.860M
US$ 10.15
0.39 4.00
96,112
36.58M
US$ 371.290M
US$ 2.30
0.17 7.98
2.26M
155.15M
US$ 356.840M
US$ 3.09
0.32 11.55
1.62M
114.86M
US$ 354.920M
US$ 7.85
-0.24 -2.97
1.14M
45.20M
US$ 354.820M
US$ 1.33
-0.02 -1.48
1.16M
266.12M
US$ 353.940M
US$ 7.39
-0.10 -1.34
136,432
47.55M
US$ 351.390M
US$ 3.98
0.16 4.19
716,349
85.69M
US$ 341.050M
US$ 4.77
0.08 1.71
533,297
70.57M
US$ 336.620M
US$ 4.42
0.16 3.76
609,315
74.24M
US$ 328.140M
US$ 1.16
-0.01 -0.85
958,420
282.73M
US$ 327.970M
US$ 4.55
0.15 3.41
2.07M
71.12M
US$ 323.600M
US$ 7.28
0.03 0.41
25,630
43.64M
US$ 317.700M
US$ 13.58
-0.06 -0.44
31,344
23.22M
US$ 315.330M
US$ 7.05
-0.58 -7.60
28,675
44.54M
US$ 314.010M
US$ 8.13
0.27 3.44
157,979
37.42M
US$ 304.220M
US$ 1.45
0.05 3.57
2.05M
209.67M
US$ 304.020M
US$ 16.85
0.36 2.18
103,250
17.61M
US$ 296.730M
US$ 5.94
-0.22 -3.57
624,507
49.55M
US$ 294.330M
US$ 7.25
-0.58 -7.41
2,267
39.63M
US$ 287.320M
US$ 10.53
0.23 2.23
353,403
27.09M
US$ 285.260M
US$ 1.84
0.00 0.00
787,549
152.10M
US$ 279.860M
US$ 4.55
0.14 3.17
693,288
61.44M
US$ 279.550M
US$ 4.03
-0.19 -4.50
957,522
68.38M
US$ 275.570M
US$ 5.01
-0.06 -1.18
292,263
54.41M
US$ 272.590M
US$ 10.50
-0.07 -0.66
96,166
25.73M
US$ 270.170M
US$ 3.19
-0.10 -3.04
680,682
84.69M
US$ 270.160M
US$ 5.36
-0.04 -0.74
129,069
49.95M
US$ 267.730M
US$ 1.30
0.12 10.17
1.00M
204.94M
US$ 266.420M
US$ 5.90
-0.09 -1.50
204,909
44.40M
US$ 261.960M
US$ 3.10
0.08 2.65
770,544
83.94M
US$ 260.210M
US$ 4.98
0.01 0.20
445,676
51.59M
US$ 256.920M
US$ 5.74
0.78 15.73
1.13M
44.51M
US$ 255.490M
US$ 7.62
0.11 1.46
218,706
33.42M
US$ 254.660M
US$ 1.78
0.06 3.49
2.22M
141.84M
US$ 252.480M
US$ 4.33
-0.04 -0.92
504,180
58.31M
US$ 252.480M
US$ 2.97
-0.03 -1.00
1.64M
84.46M
US$ 250.850M
US$ 21.18
0.65 3.17
14,638
11.78M
US$ 249.500M
US$ 1.47
0.05 3.52
1.66M
167.80M
US$ 246.670M
US$ 39.59
1.57 4.13
11,727
6.10M
US$ 241.500M
US$ 1.30
0.00 0.00
1.00M
185.72M
US$ 241.440M
US$ 6.51
0.29 4.66
1.01M
36.53M
US$ 237.810M
US$ 5.16
-6.34 -55.13
518,533
45.06M
US$ 232.510M
US$ 33.11
1.10 3.44
26,022
6.99M
US$ 231.440M
US$ 2.51
0.01 0.40
1.12M
91.18M
US$ 228.860M
US$ 1.54
0.09 6.21
12,571
145.46M
US$ 224.010M
US$ 2.20
0.00 0.00
690,171
100.33M
US$ 220.730M
US$ 1.79
0.02 1.13
762,076
121.01M
US$ 216.610M
US$ 1.68
0.13 8.39
3.07M
128.67M
US$ 216.170M
US$ 4.64
0.00 0.00
459,817
46.03M
US$ 213.580M
US$ 19.44
0.26 1.36
113,100
10.95M
US$ 212.870M
US$ 3.80
0.33 9.51
103,689
55.59M
US$ 211.240M
US$ 4.84
-0.88 -15.38
803,516
43.59M
US$ 210.980M
US$ 4.69
0.15 3.30
107,273
44.79M
US$ 210.070M
US$ 3.24
0.01 0.31
766,218
64.26M
US$ 208.200M
C$ 2.96
-0.02 -0.67
13,755
70.31M
C$ 208.120M
US$ 14.02
0.55 4.08
92,721
14.65M
US$ 205.390M
US$ 4.57
0.04 0.88
520,860
44.48M
US$ 203.270M
US$ 0.68
0.03 4.72
3.52M
291.32M
US$ 199.260M
US$ 3.50
0.12 3.55
91,313
56.62M
US$ 198.170M
US$ 4.03
-0.01 -0.25
579,658
48.13M
US$ 193.960M
US$ 2.60
0.00 0.00
376,409
73.63M
US$ 191.440M
US$ 0.84
0.01 1.43
680,946
226.60M
US$ 190.800M
US$ 2.85
0.04 1.42
1.98M
66.52M
US$ 189.580M
US$ 0.52
0.02 3.80
2.64M
361.49M
US$ 187.610M
US$ 0.95
-0.01 -1.44
4.49M
197.04M
US$ 187.190M
US$ 4.20
-0.28 -6.25
497,498
44.20M
US$ 185.640M
US$ 17.10
0.81 4.97
138,464
10.79M
US$ 184.510M
US$ 2.57
0.04 1.58
4,921
70.10M
US$ 180.160M
US$ 2.99
-0.01 -0.33
143,897
59.74M
US$ 178.620M
US$ 3.29
0.23 7.52
345,778
53.94M
US$ 177.460M
US$ 3.36
0.05 1.36
15,157
52.36M
US$ 175.670M
US$ 3.51
0.00 0.00
0
49.91M
US$ 175.180M
US$ 3.16
0.03 0.96
337,645
54.63M
US$ 172.630M
US$ 2.11
-0.01 -0.47
553,215
81.38M
US$ 171.710M
US$ 8.87
0.17 1.95
127,550
19.32M
US$ 171.270M
US$ 11.49
0.72 6.69
185,042
14.85M
US$ 170.630M
US$ 3.55
0.27 8.14
2,475
47.40M
US$ 168.270M
US$ 11.47
0.00 0.00
80,508
14.48M
US$ 166.090M
US$ 7.98
0.07 0.88
59,687
20.52M
US$ 163.750M
US$ 1.97
0.03 1.55
4,210
82.78M
US$ 163.080M
US$ 1.24
0.00 0.00
454,821
131.16M
US$ 162.640M
C$ 4.56
0.12 2.70
11,350
35.62M
C$ 162.430M
US$ 7.32
0.01 0.14
168,469
22.17M
US$ 162.280M
US$ 2.75
0.11 4.17
928,275
57.94M
US$ 159.340M
US$ 8.00
1.25 18.52
46,888
19.53M
US$ 156.240M
US$ 1.46
0.03 2.10
833,526
106.59M
US$ 155.620M
US$ 3.54
0.07 2.02
46,951
42.76M
US$ 151.370M
US$ 0.72
0.03 5.06
3.16M
208.65M
US$ 150.230M
US$ 2.84
0.48 20.34
713,648
52.62M
US$ 149.440M
US$ 7.35
-0.10 -1.34
984,204
19.99M
US$ 146.930M
US$ 1.48
-0.62 -29.52
63,275
98.94M
US$ 146.430M
US$ 3.97
0.40 11.20
6,688
36.86M
US$ 146.330M
US$ 1.45
0.02 1.05
35,802
100.09M
US$ 144.630M
US$ 3.06
0.15 5.15
377,023
46.23M
US$ 141.460M
US$ 2.86
-0.02 -0.69
223,686
49.09M
US$ 140.400M
US$ 5.08
-0.02 -0.39
37,693
27.43M
US$ 139.340M
US$ 3.87
0.12 3.20
279,154
35.85M
US$ 138.740M
US$ 1.29
0.01 0.78
471,181
107.42M
US$ 138.570M
US$ 2.06
0.12 6.19
1.32M
65.50M
US$ 134.930M
US$ 3.90
-0.10 -2.50
445,958
34.32M
US$ 133.850M
US$ 1.47
0.02 1.38
243,659
89.54M
US$ 131.620M
US$ 2.19
0.18 8.96
1.87M
59.55M
US$ 130.410M
US$ 1.88
-0.10 -5.05
161,386
69.36M
US$ 130.400M
US$ 13.90
0.44 3.27
82,272
9.37M
US$ 130.240M
US$ 1.12
0.11 10.89
2.99M
115.21M
US$ 129.040M
US$ 2.57
0.02 0.78
248,514
50.04M
US$ 128.600M
US$ 1.81
0.06 3.43
550,874
70.57M
US$ 127.730M
US$ 0.43
-0.005 -1.14
1.16M
292.16M
US$ 126.800M
US$ 1.11
0.06 5.71
1.68M
113.89M
US$ 126.420M
US$ 1.14
-0.46 -28.75
598,390
107.02M
US$ 122.000M
US$ 1.91
0.07 3.80
1.09M
63.81M
US$ 121.880M
US$ 1.14
0.00 0.00
467,969
105.91M
US$ 120.740M
US$ 1.08
0.01 0.93
14,628
111.42M
US$ 120.330M
US$ 8.95
0.11 1.24
73,352
13.14M
US$ 117.600M
US$ 0.64
0.03 4.81
1.96M
184.46M
US$ 117.320M
US$ 1.21
0.05 4.31
163,911
96.69M
US$ 116.990M
C$ 1.80
-0.01 -0.55
12,905
64.94M
C$ 116.890M
US$ 1.07
0.18 20.22
383,851
103.82M
US$ 111.090M
US$ 7.97
-0.34 -4.09
26,191
13.70M
US$ 109.190M
US$ 5.10
0.17 3.45
185,923
21.19M
US$ 108.070M
US$ 1.97
-0.02 -0.76
215,099
54.92M
US$ 107.920M
US$ 2.85
-0.01 -0.35
40,537
37.82M
US$ 107.790M
US$ 1.28
0.01 0.79
744,321
82.55M
US$ 105.660M
US$ 0.65
0.02 2.70
906,736
161.56M
US$ 104.530M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 2.55
0.03 1.19
1.54M
39.95M
US$ 101.870M
US$ 0.79
-0.0049 -0.62
1.03M
127.97M
US$ 101.220M
US$ 15.46
0.15 0.98
35,642
6.53M
US$ 100.920M
US$ 0.62
-0.16 -20.52
1.44M
153.83M
US$ 95.370M
US$ 0.76
0.03 4.80
87,363
125.56M
US$ 95.170M
US$ 1.29
0.03 2.38
906,887
71.27M
US$ 91.940M
US$ 1.30
0.02 1.17
1.14M
70.38M
US$ 91.140M
US$ 2.63
0.06 2.33
60,301
34.54M
US$ 90.840M
US$ 0.41
-0.0068 -1.63
1.64M
220.42M
US$ 90.370M
US$ 1.44
0.07 5.11
180,869
62.76M
US$ 90.370M
US$ 0.92
-0.06 -5.96
478,362
97.93M
US$ 90.100M
US$ 2.71
0.43 18.86
613,122
33.08M
US$ 89.650M
US$ 2.94
-0.02 -0.68
44,614
30.48M
US$ 89.610M
US$ 1.47
0.03 2.08
759,362
60.85M
US$ 89.450M
US$ 0.98
0.04 3.98
240,955
90.08M
US$ 88.280M
US$ 4.62
0.24 5.48
140,565
19.05M
US$ 88.010M
US$ 5.26
0.04 0.77
73,548
16.71M
US$ 87.890M
US$ 2.72
-0.03 -1.09
18,953
32.20M
US$ 87.580M
US$ 2.15
-0.05 -2.27
39,455
40.31M
US$ 86.670M
US$ 1.74
-0.08 -4.40
95,658
49.63M
US$ 86.360M
C$ 1.10
0.10 10.00
41,864
78.16M
C$ 85.980M
C$ 1.15
0.00 0.00
0
74.57M
C$ 85.760M
US$ 1.69
0.04 2.42
104,482
49.81M
US$ 84.180M
US$ 1.44
0.08 5.88
673,587
56.59M
US$ 81.490M
US$ 0.65
0.00 0.00
122,512
124.54M
US$ 80.950M
US$ 9.80
0.31 3.27
329,932
8.25M
US$ 80.850M
US$ 2.79
0.11 4.10
176,602
28.91M
US$ 80.660M
US$ 1.23
0.08 6.96
272,421
65.29M
US$ 80.310M
US$ 1.86
0.03 1.64
285,593
43.17M
US$ 80.300M
US$ 1.79
0.02 1.13
182,727
44.39M
US$ 79.460M
US$ 1.26
0.08 6.78
761,164
62.76M
US$ 79.080M
US$ 0.62
0.02 2.98
436,614
125.80M
US$ 78.370M
US$ 0.34
-0.0049 -1.40
830,935
227.48M
US$ 78.250M
US$ 1.07
0.01 0.94
872,238
70.71M
US$ 75.660M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 2.48
-0.01 -0.40
54,985
29.75M
US$ 73.780M
US$ 6.03
0.11 1.86
121,421
12.18M
US$ 73.450M
C$ 0.64
0.01 1.59
51,500
113.60M
C$ 72.700M
US$ 1.45
0.00 0.00
6,974
49.05M
US$ 71.120M
US$ 3.88
0.0011 0.03
10,199
18.29M
US$ 70.970M
US$ 1.44
0.14 10.77
1.03M
49.09M
US$ 70.690M
US$ 1.71
0.20 13.25
81,641
40.88M
US$ 69.900M
US$ 1.50
-0.01 -0.66
78,965
46.60M
US$ 69.900M
US$ 1.44
0.04 2.86
1.20M
48.11M
US$ 69.280M
US$ 0.85
0.0037 0.44
34,005
81.50M
US$ 68.870M
US$ 1.99
-0.82 -29.18
258,597
34.39M
US$ 68.440M
US$ 2.21
0.19 9.41
387,254
30.67M
US$ 67.780M
US$ 1.53
-0.16 -9.20
14,158
44.27M
US$ 67.730M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
C$ 0.10
0.005 5.56
74,395
701.73M
C$ 66.660M
US$ 0.39
-0.0099 -2.48
2.73M
170.74M
US$ 66.590M
US$ 0.74
0.0019 0.26
993,418
90.55M
US$ 66.550M
US$ 1.79
0.03 1.70
10,857
36.83M
US$ 65.930M
C$ 0.20
0.02 8.11
123,900
328.48M
C$ 65.700M
US$ 0.63
0.03 5.35
189,711
103.80M
US$ 65.390M
US$ 0.86
-0.0098 -1.13
267,544
75.84M
US$ 65.220M
US$ 5.51
-0.10 -1.81
10,866
11.80M
US$ 65.020M
US$ 4.12
-1.25 -23.28
65,027
15.53M
US$ 63.980M
US$ 10.02
0.01 0.10
7,126
6.36M
US$ 63.730M
US$ 0.84
-0.02 -2.55
50,912
75.00M
US$ 63.220M
C$ 2.30
-0.10 -4.17
8,744
27.40M
C$ 63.020M
US$ 1.74
0.02 1.16
336,846
36.10M
US$ 62.810M
US$ 1.06
0.01 0.95
49,235
58.88M
US$ 62.410M
US$ 1.70
0.11 6.92
873,562
36.24M
US$ 61.610M
US$ 0.51
0.04 9.06
1.53M
119.62M
US$ 61.480M
US$ 2.26
0.01 0.44
147,422
26.97M
US$ 60.950M
US$ 2.93
-0.05 -1.68
307,781
20.80M
US$ 60.940M
US$ 0.24
-0.01 -4.80
306,543
255.88M
US$ 60.900M
US$ 17.00
2.01 13.41
534
3.55M
US$ 60.350M
US$ 3.97
0.05 1.28
84,864
15.00M
US$ 59.550M
US$ 2.11
0.04 1.93
70,892
27.84M
US$ 58.740M
US$ 1.22
0.11 9.91
313,643
48.10M
US$ 58.680M
US$ 0.90
-0.06 -6.43
304,126
64.24M
US$ 57.820M
US$ 0.96
0.03 3.12
295,481
59.47M
US$ 57.270M
US$ 1.52
0.04 2.70
331,056
37.42M
US$ 56.880M
US$ 0.86
-0.03 -3.37
42,832
65.88M
US$ 56.660M
US$ 1.81
-3.55 -66.23
235,136
31.14M
US$ 56.360M
US$ 5.05
0.02 0.40
3,613
11.11M
US$ 56.110M
US$ 0.35
-0.007 -1.94
390,159
158.72M
US$ 56.030M
US$ 2.24
-0.06 -2.61
289,094
24.29M
US$ 54.410M
US$ 0.90
-0.99 -52.33
499,508
60.08M
US$ 54.130M
US$ 1.10
0.02 1.85
513,123
48.88M
US$ 53.770M
US$ 0.89
0.008 0.91
12,769
60.34M
US$ 53.580M
US$ 1.11
0.00 0.00
144,581
48.26M
US$ 53.570M
US$ 1.71
-0.20 -10.47
7,189
31.24M
US$ 53.420M
US$ 1.02
0.02 2.00
87,828
51.75M
US$ 52.780M
US$ 1.30
0.04 3.17
15,425
40.30M
US$ 52.390M
US$ 19.91
1.09 5.79
15,663
2.61M
US$ 51.970M
US$ 4.77
-0.09 -1.85
15,548
10.79M
US$ 51.470M
US$ 0.66
0.03 4.18
589,537
78.26M
US$ 51.340M
US$ 1.20
0.05 4.35
868,453
42.51M
US$ 51.010M
US$ 10.10
0.00 0.00
0
5.02M
US$ 50.700M
US$ 5.25
0.00 0.00
0
9.39M
US$ 49.300M
US$ 2.08
0.43 26.06
710,817
23.61M
US$ 49.110M
US$ 5.50
0.01 0.18
4,377
8.91M
US$ 49.000M
C$ 0.69
0.00 0.00
0
70.89M
C$ 48.910M
US$ 2.84
0.01 0.35
7,913
16.84M
US$ 47.830M
US$ 1.80
0.06 3.45
152,910
26.53M
US$ 47.750M
US$ 0.89
0.07 8.81
2.20M
53.33M
US$ 47.410M
US$ 0.82
-0.0001 -0.01
182,487
57.49M
US$ 47.140M
C$ 0.35
0.00 0.00
41,500
134.53M
C$ 47.090M
US$ 7.34
0.08 1.10
17,459
6.39M
US$ 46.900M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 4.41
-0.22 -4.75
73,455
10.50M
US$ 46.300M
US$ 0.54
0.04 8.80
660,277
85.03M
US$ 46.260M
US$ 2.70
0.28 11.57
5.67M
17.06M
US$ 46.060M
US$ 5.48
-0.52 -8.68
31,195
8.19M
US$ 44.870M
US$ 1.23
0.05 4.24
6,902
36.18M
US$ 44.500M
US$ 0.49
0.01 2.25
340,895
90.56M
US$ 44.370M
C$ 0.93
-0.02 -2.11
34,000
47.65M
C$ 44.310M
US$ 0.36
0.02 5.72
2.66M
123.53M
US$ 43.850M
US$ 0.99
-0.01 -1.00
117,222
44.00M
US$ 43.560M
US$ 1.44
-0.15 -9.18
573,148
30.34M
US$ 43.540M
US$ 1.33
0.10 8.13
191,885
32.60M
US$ 43.360M
US$ 0.53
-0.05 -7.93
367,154
82.40M
US$ 43.340M
US$ 0.53
-0.02 -2.78
1.34M
82.46M
US$ 43.290M
US$ 0.56
-0.007 -1.23
224,757
77.07M
US$ 43.240M
US$ 1.53
0.03 2.00
140,451
27.60M
US$ 42.230M
US$ 1.19
0.10 9.17
348,896
35.20M
US$ 41.890M
US$ 2.07
0.45 27.78
60,269
20.16M
US$ 41.730M
US$ 1.22
0.03 2.52
83,111
34.08M
US$ 41.580M
US$ 1.01
-0.03 -2.88
5,839
41.08M
US$ 41.490M
US$ 1.22
0.09 7.97
55,990
33.84M
US$ 41.280M
US$ 0.75
0.01 1.89
38,326
54.52M
US$ 41.110M
US$ 0.92
0.07 8.37
164,240
44.56M
US$ 40.950M
US$ 0.74
-0.09 -10.96
104,865
55.25M
US$ 40.830M
US$ 1.55
0.01 0.65
58,280
26.16M
US$ 40.550M
US$ 1.08
0.04 3.85
120,838
37.41M
US$ 40.400M
US$ 4.14
-0.01 -0.24
128,868
9.72M
US$ 40.240M
US$ 1.27
0.02 1.60
61,108
31.05M
US$ 39.430M
US$ 1.17
0.02 1.74
69,099
33.31M
US$ 38.970M
US$ 3.10
0.25 8.77
3,114
12.54M
US$ 38.870M
US$ 0.33
0.03 9.61
1.78M
116.36M
US$ 38.750M
US$ 5.02
0.01 0.20
99,709
7.67M
US$ 38.500M
C$ 0.78
0.00 0.00
0
49.02M
C$ 38.240M
US$ 1.21
-0.04 -3.20
322,683
31.20M
US$ 37.750M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 0.77
0.02 2.37
143,901
47.74M
US$ 36.900M
US$ 3.42
-0.07 -2.01
8,210
10.78M
US$ 36.870M
US$ 1.70
0.05 3.03
7,371
21.67M
US$ 36.840M
US$ 2.89
-0.04 -1.37
10,206
12.65M
US$ 36.560M
US$ 0.78
0.07 10.30
330,105
46.58M
US$ 36.430M
US$ 1.23
-0.01 -0.81
13,961
29.59M
US$ 36.400M
US$ 1.45
0.08 5.84
297,882
24.91M
US$ 36.120M
US$ 2.52
0.32 14.55
697,982
14.23M
US$ 35.860M
US$ 0.45
-0.01 -2.58
995,194
79.22M
US$ 35.650M
US$ 6.17
0.33 5.65
24,042
5.76M
US$ 35.540M
US$ 1.56
-0.09 -5.18
60,533
22.48M
US$ 34.960M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 1.31
0.08 6.50
116,741
26.30M
US$ 34.450M
US$ 0.75
-0.0059 -0.78
374,598
45.72M
US$ 34.380M
US$ 0.81
0.04 5.19
222,201
42.18M
US$ 34.170M
US$ 0.19
-0.0043 -2.20
898,682
170.55M
US$ 32.580M
US$ 1.53
-0.04 -2.55
125,611
21.24M
US$ 32.500M
US$ 0.41
0.0051 1.28
305,959
79.97M
US$ 32.390M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 1.21
0.11 9.55
17,443
26.47M
US$ 31.900M
US$ 1.42
0.11 8.40
64,790
22.30M
US$ 31.670M
US$ 0.87
0.03 3.54
6,275
36.18M
US$ 31.330M
US$ 9.57
-0.03 -0.31
4,214
3.25M
US$ 31.100M
US$ 3.50
0.10 2.94
9,130
8.74M
US$ 30.590M
US$ 4.16
0.10 2.46
3,531
7.30M
US$ 30.370M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
C$ 0.27
0.00 0.00
7,728
111.72M
C$ 30.160M
US$ 1.94
0.009 0.47
16,557
15.49M
US$ 30.040M
US$ 16.75
0.55 3.40
21,322
1.78M
US$ 29.820M
US$ 1.08
0.03 2.86
232,868
27.52M
US$ 29.720M
US$ 0.33
0.003 0.93
1.97M
89.34M
US$ 29.120M
US$ 0.55
-0.01 -1.79
335,687
52.74M
US$ 29.010M
US$ 0.71
0.005 0.71
2,391
40.23M
US$ 28.560M
US$ 0.28
0.0054 1.95
565,929
100.77M
US$ 28.520M
US$ 2.46
0.13 5.58
1,118
11.54M
US$ 28.390M
US$ 1.85
-0.01 -0.54
34,931
15.10M
US$ 27.940M
US$ 2.42
0.00 0.00
2,771
11.45M
US$ 27.710M
US$ 0.79
-0.01 -1.39
777,405
34.96M
US$ 27.620M
US$ 1.85
0.05 2.49
81,107
14.75M
US$ 27.290M
C$ 0.18
0.00 0.00
0
148.22M
C$ 26.680M
US$ 1.38
-0.12 -8.07
31,328
19.08M
US$ 26.310M
US$ 0.39
0.05 13.00
404,277
66.79M
US$ 26.180M
C$ 0.56
0.00 0.00
0
46.03M
C$ 25.780M
US$ 3.08
0.08 2.67
11,448
8.36M
US$ 25.750M
US$ 8.44
-3.11 -26.93
56,874
3.04M
US$ 25.660M
US$ 2.90
-0.02 -0.52
5,568
8.70M
US$ 25.190M
US$ 1.02
-0.01 -0.97
110,833
24.00M
US$ 24.480M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
C$ 0.19
0.00 0.00
0
127.82M
C$ 24.290M
US$ 1.03
0.002 0.19
153,718
23.23M
US$ 24.000M
US$ 10.00
0.72 7.76
72,570
2.40M
US$ 24.000M
US$ 1.37
-0.04 -2.50
101,065
17.55M
US$ 23.960M
US$ 3.00
-0.02 -0.66
17,010
7.98M
US$ 23.940M
US$ 1.93
0.00 0.00
85,480
12.09M
US$ 23.330M
US$ 6.36
0.84 15.22
12,327
3.65M
US$ 23.210M
US$ 0.39
0.06 16.72
2.71M
59.12M
US$ 22.820M
US$ 1.26
-0.02 -1.56
70,811
18.06M
US$ 22.760M
US$ 4.03
0.41 11.33
32,746
5.56M
US$ 22.410M
US$ 0.28
-0.0012 -0.42
63,192
77.45M
US$ 22.000M
US$ 0.05
-0.0035 -6.09
35,000
407.29M
US$ 21.990M
US$ 2.09
0.05 2.45
20,018
10.14M
US$ 21.190M
US$ 1.11
-0.05 -4.31
42,084
18.86M
US$ 20.930M
US$ 1.55
0.01 0.65
4,205
13.48M
US$ 20.890M
US$ 0.64
0.02 3.42
97,633
32.69M
US$ 20.760M
US$ 0.33
0.001 0.30
167,598
61.77M
US$ 20.380M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 0.28
0.01 4.84
223,410
71.01M
US$ 20.170M
US$ 0.85
0.27 46.42
224,310
23.69M
US$ 20.160M
US$ 1.46
0.05 3.55
108,066
13.35M
US$ 19.490M
C$ 0.22
0.01 4.88
10,000
88.52M
C$ 19.030M
US$ 2.26
0.18 8.46
4,828
8.39M
US$ 18.930M
US$ 0.26
-0.0025 -0.97
2.41M
74.11M
US$ 18.900M
US$ 1.32
-0.08 -5.93
178,617
14.35M
US$ 18.900M
US$ 0.86
-0.005 -0.58
12,135
21.99M
US$ 18.800M
US$ 2.74
-0.01 -0.36
2,690
6.80M
US$ 18.630M
US$ 0.32
0.0059 1.87
101,052
58.02M
US$ 18.620M
US$ 5.32
-0.13 -2.39
14,014
3.41M
US$ 18.140M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 3.88
0.04 1.04
8,155
4.59M
US$ 17.810M
US$ 1.22
-0.04 -3.17
73,580
13.80M
US$ 16.840M
US$ 0.47
0.03 7.91
82,046
35.43M
US$ 16.720M
US$ 3.30
2.59 366.17
195,954
5.04M
US$ 16.630M
US$ 3.46
-0.02 -0.58
13,506
4.75M
US$ 16.410M
US$ 0.97
0.02 1.89
36,012
16.85M
US$ 16.340M
C$ 0.03
0.00 0.00
114,786
541.70M
C$ 16.250M
US$ 4.68
0.11 2.41
79,065
3.46M
US$ 16.190M
US$ 3.00
-0.01 -0.33
4,208
5.35M
US$ 16.050M
US$ 0.39
0.01 3.72
273,334
40.44M
US$ 15.690M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 0.37
-0.0012 -0.32
290,005
41.55M
US$ 15.460M
C$ 0.16
0.005 3.23
15,600
96.40M
C$ 15.420M
US$ 0.55
0.07 14.58
5.75M
27.86M
US$ 15.320M
US$ 0.82
0.03 3.38
69,343
17.77M
US$ 14.570M
US$ 0.22
0.001 0.45
38,312
64.53M
US$ 14.390M
US$ 0.16
-0.02 -10.31
119,000
88.13M
US$ 14.190M
US$ 0.36
-0.006 -1.63
325,563
38.32M
US$ 13.910M
US$ 4.24
0.06 1.44
61,554
3.21M
US$ 13.610M
US$ 0.44
0.01 2.58
264,721
31.06M
US$ 13.600M
US$ 0.35
-0.21 -37.39
32,768
38.27M
US$ 13.390M
C$ 0.10
0.00 0.00
0
140.64M
C$ 13.360M
US$ 1.31
0.00 0.00
1,245
10.17M
US$ 13.320M
US$ 1.97
0.02 0.82
4,075
6.66M
US$ 13.090M
C$ 0.03
0.00 0.00
180,108
418.56M
C$ 12.560M
US$ 1.06
0.05 4.95
5,670
11.70M
US$ 12.400M
C$ 0.09
-0.005 -5.26
95,000
137.51M
C$ 12.380M
US$ 0.30
0.02 5.58
239,280
41.27M
US$ 12.340M
US$ 0.96
0.05 5.80
316,318
12.85M
US$ 12.340M
US$ 1.15
0.07 6.48
38,197
10.71M
US$ 12.320M
US$ 0.85
-0.01 -1.65
78,042
14.50M
US$ 12.280M
US$ 1.75
0.02 1.17
27,300
6.92M
US$ 12.110M
US$ 6.30
0.06 0.96
27,968
1.92M
US$ 12.100M
US$ 0.73
0.008 1.10
15,188
16.39M
US$ 12.030M
US$ 0.46
-0.002 -0.43
463,588
25.92M
US$ 12.000M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 1.16
-0.07 -5.69
37,723
10.17M
US$ 11.800M
C$ 0.09
0.005 5.88
30,000
129.86M
C$ 11.690M
US$ 0.16
0.0034 2.16
478,723
72.48M
US$ 11.670M
US$ 2.23
0.12 5.69
200
5.17M
US$ 11.530M
US$ 2.70
0.00 0.00
1.62M
4.17M
US$ 11.260M
C$ 0.04
-0.005 -11.11
270,003
280.65M
C$ 11.230M
US$ 1.60
0.08 5.19
2,084
6.99M
US$ 11.180M
US$ 1.31
0.02 1.55
75,286
8.47M
US$ 11.100M
US$ 1.89
0.18 10.70
1,448
5.70M
US$ 10.790M
US$ 1.75
0.50 39.44
76.90M
6.03M
US$ 10.550M
US$ 0.25
-0.0018 -0.71
27,587
41.49M
US$ 10.370M
US$ 1.14
0.01 0.88
66,906
8.99M
US$ 10.250M
US$ 0.37
0.03 9.02
264,801
28.01M
US$ 10.220M
US$ 0.41
-0.01 -3.22
93,203
25.15M
US$ 10.210M
US$ 0.28
0.00 0.00
0
36.47M
US$ 10.030M
US$ 0.18
-0.0038 -2.07
89,093
51.37M
US$ 9.250M
US$ 0.23
0.004 1.75
53,552
38.67M
US$ 9.010M
US$ 2.83
0.01 0.35
3,088
3.12M
US$ 8.830M
US$ 1.92
0.01 0.52
2,716
4.58M
US$ 8.790M
US$ 7.84
1.09 16.15
748,731
1.12M
US$ 8.780M
US$ 0.29
-0.002 -0.68
101,312
30.17M
US$ 8.750M
US$ 5.14
0.03 0.59
5,310
1.63M
US$ 8.380M
US$ 2.79
0.04 1.45
4,026
3.00M
US$ 8.370M
US$ 0.89
-0.09 -9.17
515,650
9.39M
US$ 8.360M
US$ 1.19
0.04 3.48
13,353
6.97M
US$ 8.290M
US$ 0.97
-0.02 -2.12
74,066
8.47M
US$ 8.200M
US$ 1.50
-0.04 -2.41
11,664
5.43M
US$ 8.140M
US$ 0.19
-0.0089 -4.43
254,225
41.75M
US$ 8.020M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 0.83
-0.07 -8.02
470,237
9.44M
US$ 7.840M
US$ 2.26
-0.08 -3.42
4,245
3.47M
US$ 7.840M
US$ 0.55
0.0049 0.91
98,546
14.09M
US$ 7.680M
US$ 0.33
-0.01 -3.79
20,556
23.13M
US$ 7.630M
US$ 0.77
-0.0003 -0.04
6,966
9.66M
US$ 7.470M
US$ 2.75
0.07 2.61
2,502
2.71M
US$ 7.450M
US$ 2.84
0.33 13.15
14,440
2.58M
US$ 7.330M
US$ 1.20
-0.03 -2.44
497,032
6.10M
US$ 7.320M
US$ 0.37
-0.05 -11.90
151,488
19.49M
US$ 7.270M
US$ 3.16
-0.01 -0.32
65,890
2.30M
US$ 7.270M
US$ 1.98
-0.01 -0.50
17,351
3.65M
US$ 7.230M
US$ 5.95
0.06 1.02
5,457
1.10M
US$ 6.540M
US$ 1.01
-0.01 -0.98
10,440
6.15M
US$ 6.210M
C$ 0.02
-0.005 -20.00
250,000
308.61M
C$ 6.170M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 0.48
-0.003 -0.62
18,535
12.01M
US$ 5.760M
US$ 0.09
-0.005 -5.43
1.19M
65.46M
US$ 5.700M
US$ 3.50
-0.65 -15.66
3
1.61M
US$ 5.640M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 0.79
0.01 1.84
571,021
6.90M
US$ 5.440M
US$ 2.10
0.04 1.94
33,095
2.51M
US$ 5.270M
US$ 0.22
-0.20 -47.90
39.70M
23.46M
US$ 5.160M
US$ 2.27
0.02 0.89
7,450
2.23M
US$ 5.060M
US$ 0.88
0.08 10.19
55,656
5.70M
US$ 4.990M
US$ 1.14
0.17 17.53
9.81M
4.38M
US$ 4.990M
US$ 0.12
-0.004 -3.25
4.13M
41.30M
US$ 4.910M
US$ 1.08
0.05 4.37
14,214
4.48M
US$ 4.820M
US$ 0.65
0.00 0.00
0
7.24M
US$ 4.710M
US$ 0.72
0.0021 0.29
18,007
6.47M
US$ 4.650M
C$ 0.12
0.00 0.00
0
38.74M
C$ 4.650M
US$ 8.92
0.59 7.08
76,676
505,798
US$ 4.510M
US$ 0.83
-0.08 -9.17
105,627
5.35M
US$ 4.450M
US$ 0.99
-0.04 -3.50
181,364
4.34M
US$ 4.310M
C$ 0.10
-0.005 -5.00
67,500
44.79M
C$ 4.260M
US$ 0.09
0.00 0.00
0
47.10M
US$ 4.190M
US$ 0.94
0.14 17.93
1.89M
4.43M
US$ 4.160M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
C$ 0.05
0.00 0.00
102,000
90.29M
C$ 4.060M
US$ 1.46
0.03 2.10
15,929
2.76M
US$ 4.030M
US$ 2.51
-0.16 -5.99
16,296
1.60M
US$ 4.020M
US$ 0.02
0.00 0.00
0
261.79M
US$ 3.930M
US$ 0.66
-0.01 -1.89
511,479
5.90M
US$ 3.890M
C$ 0.05
0.00 0.00
0
76.84M
C$ 3.840M
US$ 3.52
-0.38 -9.74
51,605
1.09M
US$ 3.840M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 1.26
0.03 2.44
28,472
3.01M
US$ 3.790M
US$ 1.36
0.03 2.64
12,349
2.78M
US$ 3.770M
US$ 2.43
0.02 0.87
6,049
1.54M
US$ 3.740M
US$ 0.25
-0.10 -28.57
11,149
14.89M
US$ 3.720M
US$ 0.67
-0.04 -5.63
107,275
5.43M
US$ 3.640M
C$ 0.03
0.005 20.00
155,000
121.27M
C$ 3.640M
US$ 0.29
-0.03 -10.38
365,397
12.48M
US$ 3.560M
US$ 3.76
0.00 0.00
0
914,234
US$ 3.440M
US$ 1.94
-0.04 -2.02
83,002
1.75M
US$ 3.400M
US$ 0.28
0.00 0.00
0
12.27M
US$ 3.390M
US$ 0.86
-0.05 -5.18
41,463
3.93M
US$ 3.380M
US$ 2.43
0.05 2.10
4,083
1.32M
US$ 3.210M
US$ 0.95
-0.02 -2.06
130,323
3.23M
US$ 3.070M
US$ 0.28
0.01 4.58
83,562
10.83M
US$ 3.060M
US$ 0.60
0.04 6.19
20,499
5.09M
US$ 3.050M
US$ 0.60
0.01 2.04
36,711
4.89M
US$ 2.930M
US$ 2.14
-0.10 -4.30
1,136
1.36M
US$ 2.910M
US$ 2.40
-0.01 -0.41
6,962
1.21M
US$ 2.900M
US$ 2.26
0.19 9.18
1.31M
1.28M
US$ 2.890M
US$ 0.89
0.02 2.78
15,700
3.22M
US$ 2.850M
C$ 0.02
0.00 0.00
0
140.03M
C$ 2.800M
US$ 0.88
-0.04 -4.79
279,483
3.19M
US$ 2.790M
US$ 1.13
-0.10 -7.75
405
2.25M
US$ 2.540M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 3.24
-0.05 -1.52
1,337
736,431
US$ 2.390M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
C$ 0.09
0.00 0.00
0
27.30M
C$ 2.320M
US$ 1.38
0.02 1.47
36,561
1.66M
US$ 2.290M
US$ 1.75
-0.13 -6.91
131,678
1.30M
US$ 2.280M
US$ 0.32
-0.02 -6.71
1.10M
6.96M
US$ 2.230M
US$ 0.18
-0.0036 -2.02
383,766
12.59M
US$ 2.200M
US$ 1.13
0.03 2.73
4,245
1.93M
US$ 2.180M
US$ 0.15
0.00 0.00
0
14.37M
US$ 2.160M
US$ 0.24
-0.02 -6.07
1.08M
8.51M
US$ 2.040M
US$ 0.72
0.02 2.81
46,731
2.77M
US$ 1.990M
US$ 2.72
0.05 1.76
7,118
724,152
US$ 1.970M
US$ 0.38
-0.003 -0.79
100,411
4.75M
US$ 1.800M
US$ 1.38
0.01 0.73
119,928
1.27M
US$ 1.750M
US$ 0.70
-0.01 -1.91
124,081
2.51M
US$ 1.750M
US$ 1.33
-0.01 -0.75
32,223
1.30M
US$ 1.730M
US$ 2.00
0.08 4.17
16,328
852,996
US$ 1.710M
US$ 0.23
-0.02 -8.95
231,806
7.14M
US$ 1.670M
US$ 1.31
-0.001 -0.08
74,040
1.17M
US$ 1.530M
US$ 0.73
0.02 2.68
46,241
2.04M
US$ 1.490M
US$ 0.05
0.00 0.00
0
29.49M
US$ 1.470M
US$ 0.04
-0.0022 -5.09
8.53M
34.87M
US$ 1.430M
US$ 0.23
0.0096 4.44
65,367
6.29M
US$ 1.420M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
C$ 0.01
0.00 0.00
265,115
141.96M
C$ 1.420M
US$ 0.34
-0.02 -5.56
58,559
4.19M
US$ 1.420M
US$ 0.03
-0.12 -82.76
11,200
54.39M
US$ 1.360M
US$ 0.28
-0.83 -74.77
406
4.85M
US$ 1.360M
US$ 0.002
-0.0002 -9.09
5,351
635.88M
US$ 1.270M
US$ 0.86
-0.03 -3.51
171,066
1.46M
US$ 1.260M
US$ 0.10
0.00 0.00
0
12.23M
US$ 1.250M
US$ 0.004
0.0001 2.56
79,186
302.90M
US$ 1.210M
US$ 0.75
-0.02 -2.75
104,855
1.60M
US$ 1.200M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 1.18
0.00 0.00
0
863,788
US$ 1.020M
C$ 0.11
0.00 0.00
0
8.86M
C$ 975K
US$ 0.68
0.0043 0.64
46,009
1.44M
US$ 973K
US$ 0.20
0.00 0.00
0
4.44M
US$ 888K
US$ 1.43
-0.03 -2.05
89,634
580,840
US$ 831K
US$ 0.17
-0.04 -19.05
1,700
4.31M
US$ 733K
US$ 0.22
-0.03 -13.39
1.28M
3.27M
US$ 719K
US$ 0.02
-0.0078 -34.21
49,402
39.74M
US$ 596K
US$ 0.02
-0.10 -82.08
63,626
26.83M
US$ 563K
US$ 0.27
-0.16 -36.90
1,166
2.05M
US$ 543K
US$ 0.06
0.0004 0.67
1.23M
8.29M
US$ 497K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.002
0.00 0.00
0
172.20M
US$ 344K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.28
-0.08 -22.88
5.52M
696,249
US$ 191K
US$ 0.003
0.00 0.00
0
61.76M
US$ 185K
US$ 0.03
0.00 0.00
0
3.41M
US$ 109K
US$ 0.001
0.00 0.00
0
100.08M
US$ 100K
US$ 0.001
0.00 0.00
0
18.98M
US$ 19K
US$ 0.04
0.01 33.33
48,601
-
US$ -
US$ 0.00
0.00 0.00
0
44.57M
US$ -
US$ 0.00
0.00 0.00
0
54.52M
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 0.00
0.00 0.00
0
30.74M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.70M
US$ -
US$ 0.00
0.00 0.00
0
3.14M
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
6.58M
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
-0.21 -100.00
12
1.39M
US$ -
US$ 0.00
0.00 0.00
0
10.88M
US$ -
US$ 0.00
0.00 0.00
0
42.08M
US$ -
US$ 0.00
0.00 0.00
0
71.42M
US$ -
US$ 0.00
0.00 0.00
0
112.91M
US$ -
US$ 0.00
-0.0002 -100.00
9.81M
5.12B
US$ -
US$ 0.00
-0.0002 -100.00
5,000
514.01M
US$ -
US$ 0.15
0.02 15.38
11,770
-
US$ -

Latest Biotechnology Stock News


Regeneron Pharmaceuticals: Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:... Read more


Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and... Read more


Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chronic wound healing. A multi-year exclusive agreement between PAM Health and Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company at the forefront of biodynamic therapies, means Nuo’s Aurix System will serve as the sole platelet-rich plasma... Read more


Sol-Gel Technologies and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400... Read more


Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters SOUTH SAN FRANCISCO, Calif. / Apr 17, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product... Read more


Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these high-mortality cancers. Collaboration builds... Read more


Moleculin Biotech Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that an abstract regarding the Company’s next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place... Read more


Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression Enrollment completed ahead of schedule SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase... Read more


Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors... Read more


Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property... Read more


Actuate Therapeutics to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the... Read more


Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to its MEAI treatment for binge behavior.  This new US patent... Read more


Palatin Technologies Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety Bremelanotide matched or exceeded tirzepatide in appetite suppression Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation CRANBURY, N.J., April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines... Read more


Indian Patent Office Grants Acurx Pharmaceuticals Patent for DNA Polymerase IIIC Inhibitors

STATEN ISLAND, N.Y., April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This is the latest in the... Read more


Zevra Therapeutics Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of “Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann-pick type C disease” in Molecular Genetics and Metabolism. “This elucidation of MIPLYFFA’s® highly differentiated mechanism... Read more


uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression  Additional regulatory update and guidance on the Biologics License Application submission expected in the second quarter of 2025  LEXINGTON, Mass. and AMSTERDAM, April 17, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical... Read more


Covalon Technologies to Present at the Planet MicroCap Showcase: VEGAS on April 23, 2025

MISSISSAUGA, Ontario / Apr 17, 2025 / Business Wire / Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that they will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 4:30 pm (Local Time -PST). Brent Ashton, Covalon’s CEO will review why Covalon is in the “sweet spot” in the microcap sector as an undervalued,... Read more


CalciMedica Announces Presentations at Upcoming Medical Meetings

LA JOLLA, Calif., April 17, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation at Digestive Disease Week (DDW) 2025 being held May 3-6 in San Diego, CA, and the participation... Read more


Regeneron Pharmaceuticals: EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies Potential for as frequent as monthly dosing for all approved indications would provide greater dosing flexibility for physicians and patients TARRYTOWN, N.Y., April 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:... Read more


Nurix Therapeutics Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing the total amount... Read more


MedMira and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense

HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting... Read more


Ligand Pharmaceuticals Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close... Read more


NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment... Read more


Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

LEXINGTON, Mass. / Apr 17, 2025 / Business Wire / Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company’s board of directors. “Chip possesses a wealth of experience leading innovative biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board at... Read more


Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions REDWOOD CITY, Calif. & BOSTON / Apr 17, 2025 / Business Wire / Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger... Read more


Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. “It is a pleasure to welcome John to our Board,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. “John brings decades... Read more


Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the “Board”). Dr. Berman will serve as a non-voting observer to the Board through Atea’s 2025 Annual Meeting... Read more



TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease biomarkers associated with TNF-alpha activation in elderly patients with sarcopenia BALTIMORE / Apr 16, 2025 / Business Wire / TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions,... Read more


Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023 

AGOURA HILLS, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, pancreatic ductal adenocarcinoma (“PDAC”), diffuse intrinsic pontine glioma (“DIPG”), and various other cancers, today announced its financial results for the fiscal year ended December 31, 2024 (“FY 2024”), as compared to the fiscal year... Read more


Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical... Read more


GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco,... Read more



Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a potential non-invasive approach to surgical diagnosis for endometriosis MOUNTAIN VIEW, Calif. / Apr 16, 2025 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional... Read more


BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson’s disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation... Read more


Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on Wednesday, April 23, 2025 at 3:00 p.m. Pacific time. The conference is being held April 23-24 at the Seattle Convention Center. About Life Science Innovation Northwest Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s... Read more


PDS Biotechnology Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists’ IMMUNOLOGY2025™... Read more


Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission... Read more


BriaCell Therapeutics Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily pre-treated patients Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY® No Bria-IMT related discontinuations reported to date PHILADELPHIA and VANCOUVER, British... Read more


Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting

Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025. Dr. Mark Williams, Chief Science Officer of Marvel, will present on behalf of the Company and its research collaborators,... Read more


RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models Novel mechanism of action, formulation and administration: Opaganib is a differentiated oral, non-peptide therapeutic that targets sphingosine kinase-2 (SPHK2), potentially avoiding common Glucagon-like peptide-1 (GLP-1) inhibitor side effects... Read more


Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C., April 22-24, 2025. A copy of the Company’s presentation... Read more


Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid A

Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus CAMBRIDGE, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the European... Read more


Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

SIGNAL-AA Part B topline data readout on-track for 1H'26  WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical... Read more


INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced a major intellectual property milestone with respect to its next-generation mesenchymal stromal cell (MSC) product, CORDStrom™. The United States Patent and Trademark Office (USPTO), acting as the International Search Authority, has issued a favorable... Read more


Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer

Findings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer brain metastasis through the IRS2 pathway IRS2, a novel target of NT219, is identified as a driver of brain metastasis in colorectal cancer, by comprehensive research conducted by Prof. Wolf and Dr. Rubinek team at Tel Aviv University and Sourasky Medical Center REHOVOT, Israel, April 16, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company")... Read more


Conduit Pharmaceuticals Announces Leadership Changes

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as... Read more


Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations,... Read more


Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to... Read more


Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

LONDON, Ontario and BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company, today announced that the Company’s Cell Pouch Bio-hybrid Organ in clinical development as a functional cure for type 1 diabetes (T1D) will be highlighted in a panel discussion titled Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions at the 2025 Cell & Gene... Read more